Table 3.

Age- and race-adjusted ORs (95% CIs) for the association between cumulative number of HPV types and worst lesion grade detected during the first-year and first 4-year visits

Outcome, duration of follow-up, and HPV coinfection statusAll infections (persistent and transient)
Transient infections only
All HPVsAll excluding HPV-16*All excluding any HR-HPVs (low risk only)All transient HPVsTransient excluding HPV-16§Transient excluding any HR-HPVs
Any SIL
    First year visits
        01 (reference)1 (reference)1 (reference)1 (reference)1 (reference)1 (reference)
        1 type19.2 (8.5-43.4)18.5 (8.0-42.4)9.7 (3.3-28.5)10.1 (4.1-25.2)12.0 (4.8-29.8)8.1 (2.3-28.4)
        2-3 types57.0 (25.1-129.2)56.9 (24.6-131.5)18.6 (3.5-98.8)37.5 (14.6-96.3)36.0 (13.4-97.1)39.7 (6.4-245.1)
        4-6 types141.7 (42.2-476.1)102.0 (23.7-440.1)xxxx
        Ptrend**<0.001<0.001NDNDNDND
    First 4-y visits
        01 (reference)1 (reference)1 (reference)1 (reference)1 (reference)1 (reference)
        1 type8.6 (3.9-19.0)9.0 (4.0-20.0)6.3 (2.3-17.3)5.2 (2.2 -12.5)5.9 (2.4-14.2)5.0 (1.6-15.8)
        2-3 types29.2 (13.6-62.8)27.9 (12.7-61.3)6.6 (0.8-56.9)12.0 (4.8-30.3)11.5 (4.3-30.5)11.3 (1.2-104.8)
        4-8 types64.1 (27.6-148.9)53.4 (20.5-139.1)xxxx
        Ptrend<0.001<0.001NDNDNDND
HSIL only
    First year visits
        01 (reference)1 (reference)1 (reference)1 (reference)1 (reference)1 (reference)
        1 type41.5 (5.3-323.2)33.4 (4.1-268.9)14.6 (1.5-141.8)17.3 (1.8-168.0)
        2-3 types91.7 (11.6-728.1)62.4 (7.4-528.4)62.2 (6.3-617.6)47.9 (4.2-543.5)
        4-6 types424.0 (31.8-5651.8)283.7 (13.2-6111.7)xxxx
        Ptrend0.0100.102NDNDNDND
    First 4-y visits
        01 (reference)1 (reference)1 (reference)1 (reference)1 (reference)1 (reference)
        1 type20.1 (2.5-159.3)18.6 (2.3-152.1)3.1 (0.2-49.6)3.6 (0.2-58.1)
        2-3 types51.0 (6.6-395.8)30.8 (3.6-260.4)23.3 (2.0-269.4)13.0 (0.8-216.0)
        4-8 types90.1 (10.3-787.2)55.3 (4.6-658.0)xxxx
        Ptrend0.0050.199NDNDNDND
  • NOTE: Cases of any-grade SIL or HSIL were compared with subjects who were consistently HPV negative for the specified follow-up span.

    Abbreviation: ND, not determined.

  • * All women positive at least once for HPV-16 during the specified follow-up period were excluded.

  • All women positive at least once for any HR-HPVs (established or probable) during the specified follow-up period were excluded.

  • All women positive at least twice for the same HPV type during the specified follow-up period were excluded.

  • § All women positive at least twice for the same HPV type or at least once for HPV-16 during the specified follow-up period were excluded.

  • All women positive at least twice for the same HPV type or at least once for any HR-HPVs during the specified follow-up period were excluded.

  • Not estimable: combinations with either very few or no exposed subjects (x) or no lesions (—).

  • ** P for linear trend in the relation between number of types and risk among HPV-positive women only.